• About
  • Subscribe
  • Advertise
  • Contact
Saturday, February 14, 2026
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Report

An answer to visual snow syndrome? – Dr Terry Tsang & Dr Charles Shidlofsky

by Staff Writer
August 12, 2024
in Report, Soapbox
Reading Time: 5 mins read
A A
Visual snow syndrome

Dr Terry Tsang (left) and Dr Charles Shidlofsky. Images: Terry Tsang; Charles Shidlofsky.

Share on FacebookShare on Twitter

Visual snow syndrome (VSS) is a newly recognised syndrome. It has been characterised by persistent visual disturbances resembling static, akin to the noise of an untuned analog television, as well as other visual and non-visual symptoms.

This condition significantly impairs quality-of-life. Despite its pervasive impact, there have been no effective treatment modalities, primarily due to the complex and poorly understood nature of the syndrome.

However, our groundbreaking pilot study, conducted by the clinics of Dr Terry Tsang Optometry, Inc. and Neuro-Vision Associates of North Texas, offers new hope. This research explores the potential of Neuro-Optometric Rehabilitation Therapy (NORT) to reduce symptoms and enhance life quality for those afflicted.

Our work was published in the medical journal Frontiers in Neurology, and we presented our therapy to members of the Australasian College of Behavioural Optometrists.

After experiencing success with our patients, both with the reduction in visual symptoms of dots, after images, etc., and also their ability to resume function with daily living, we teamed up to design this study to help increase awareness of the possibility that neurovisual rehabilitation is a viable method to help this community.

At the time of the study design, there was no statistically trackable method for quantifying the visual symptoms that VSS patients experience. Since many experienced significant quality-of-life changes in addition to the reduction of visual snow symptoms, we chose a quality-of-life questionnaire as the assessment tool.

We used the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) as the measure to assess changes in various life aspects. These include general vision, social functioning, mental health, and dependency among others, over a structured 12-week therapy period. The objective is clear and compelling: to furnish empirical evidence on NORT’s efficacy, paving the way for its adoption as a standard care approach if proven successful.

Twenty-one participants diagnosed with VSS underwent a series of neuro-optometric sessions tailored to their specific needs, conducted by a qualified vision therapist or neuro-optometrist. The NEI-VFQ-25, a comprehensive tool for assessing vision-related quality-of-life, was administered at three key intervals: baseline, six weeks, and twelve weeks. This allowed for dynamic observation of any changes or trends that could be directly attributed to the therapy provided.

At the time of the study, NORT was not widely implemented in the clinical field for VSS, making this study among the first to delve into its potential benefits systematically. The therapy includes a variety of exercises designed to improve oculomotor function, visual processing speed, and accuracy, which are often compromised in VSS patients.

The study illuminates several key benefits of NORT:

1.    Improved general vision: Patients showed significant improvements in general vision scores from baseline to 12 weeks.

2.  Enhanced distance and near vision activities: Marked progress was noted in tasks involving distance and near vision, crucial for daily functioning.

3.  Better social functioning and mental health: There were notable enhancements in social and mental domains, suggesting that NORT could help alleviate some of the psychological burdens associated with VSS.

4.  Reduced dependency: As vision improved, patients reported a decreased reliance on others, fostering greater independence.

5.  Statistically significant results: The improvements noted were statistically significant, lending weight to the therapy’s effectiveness.

6.  Sustainable improvement: Gains in quality-of-life were not only achieved but sustained over the study period.

7.  Tailored therapeutic approach: Each patient received customised treatment, enhancing the effectiveness of the intervention.

8.  Innovative techniques: The use of advanced neuro-optometric tools and techniques provided a cutting-edge treatment framework.

9.  Safe and non-invasive: Unlike pharmacological treatments, NORT is non-invasive, presenting a lower risk profile.

10. Pioneering research: This study contributes significantly to the existing literature by filling in gaps in the understanding and management of VSS.

With the potential to significantly improve patient outcomes through a relatively unexplored therapeutic path, NORT offers a new approach to managing VSS. The detailed data analysis provides a foundation for further research, potentially influencing treatment protocols across neuro-optometry.

The holistic improvement in patients’ lives observed in this study underscores the profound impact that such therapeutic methods can have.  

About the authors

Names: Dr Terry Tsang; Dr Charles Shidlofsky

Qualifications:  FCOVD,  FAAO; OD FOVDR FNAP

Affiliations:   Optometric Vision Development & Rehabilitation Association,  Neuro-Optometric Rehabilitation (NORA); NORA president, International Sports Vision Association past president

Location: Irvine, California; Plano, Texas

Years in industry: 29; 35

More reading

Visual snow syndrome: Could mindfulness hold the key to this ‘awful’ condition?

Explaining Visual Snow Syndrome — A/Prof Clare Fraser

New treatment for Visual Snow Syndrome being presented at ACBO conference

Related Posts

The International Red Light Ophthalmic Society (IRLOS) was formerly launched at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress. Image: Eyerising

APAO 2026: Red light therapy moves into the global spotlight

by Staff Writer
February 13, 2026

The 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress, held on 5–8 February 2026 in Hong Kong, marked a defining moment...

Delegating Medicare billing responsibilities does not remove a practice’s accountability. Image: The robynmac/stock.adobe.com.

Protect your practice against Medicare fraud

by Sonya Black and Gail Wang
February 13, 2026

Practice owners and managers need to understand that risk is not just about what goes on in their clinic rooms;...

Image: Tierney/stock.adobe.com.

Special Report: Mind the (generation) gap

by Rob Mitchell
February 6, 2026

New research suggests there are many challenges when encouraging different age groups into contact lenses. But for those practices willing...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited